Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
Amna Mohamed Taha, Mohammad Aboulwafa, Hamdallah Zedan, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 13

Showing 13 citing articles:

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer
Amit Dey, Abhijit Mitra, Surajit Pathak, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 50
Peptide-based CAR-NK cells: A novel strategy for the treatment of solid tumors
Qianqian Wang, Xin Yuan, Cuijuan Liu, et al.
Biochemical Pharmacology (2025) Vol. 232, pp. 116741-116741
Closed Access | Times Cited: 1
New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition
Zeinab S. El-Fakharany, Yassin M. Nissan, Nada K. Sedky, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Personalized medicine in colorectal cancer: a comprehensive study of precision diagnosis and treatment
Fatemeh Gila, Somayeh Khoddam, Zahra Jamali, et al.
Personalized Medicine (2025), pp. 1-23
Closed Access
Enhancement of apoptosis in HCT116 and HepG2 cells by Coix lacryma-jobi var. lacryma-jobi seed extract in combination with sorafenib
Supawadee Parhira, Guo‐Yuan Zhu, Apirath Wangteeraprasert, et al.
Chinese Herbal Medicines (2025)
Open Access
Differential Impact of Intermittent vs. Sustained Hypoxia on HIF-1, VEGF and Proliferation of HepG2 Cells
Mélanie Minovès, Florence Hazane‐Puch, Giorgia Moriondo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 6875-6875
Open Access | Times Cited: 8
Direct antitumor activity of bevacizumab: an overlooked mechanism?
Zhiyong Wang, Jiaqi Li, Jinjin Guo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials
Adam Khan, Hassan Khan, Griffin Hughes, et al.
Cancer Medicine (2024) Vol. 13, Iss. 9
Open Access | Times Cited: 2
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Fernanda Andrade, Júlia German-Cortés, Sara Montero‐Herradón, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1686-1686
Open Access | Times Cited: 5
Evaluation of Ramucirumab as a combinational cancer therapeutic with 5-Aza- citidine in human Hepatoma (HuH-7) cell line
Hadeel Almasoud, Saud Alarifi, Saad Alkahtani
Journal of King Saud University - Science (2024) Vol. 36, Iss. 9, pp. 103407-103407
Open Access | Times Cited: 1
Cerbera odollam fruit extracts enhance anti-cancer activity of sorafenib in HCT116 and HepG2 cells
Supawadee Parhira, Orakot Simanurak, Khemmachat Pansooksan, et al.
Chinese Herbal Medicines (2024) Vol. 17, Iss. 1, pp. 108-126
Open Access | Times Cited: 1
Computational and experimental advances in liver-on-a-chip technology for cancer research: a systematic review
Violeta Carvalho, Mariana Ferreira, Raquel O. Rodrigues, et al.
Biophysical Reviews (2024) Vol. 17, Iss. 1, pp. 151-167
Open Access | Times Cited: 1
Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
Ting-Chao Chou
Elsevier eBooks (2024), pp. 181-218
Closed Access
Page 1

Scroll to top